Alendronate Stimulates Osteoprotegerin Expression in Fibroblasts from Periprosthetic Membrane

Purpose Aseptic loosening of an implant after total joint arthroplasty is still a major complication that results from periprosthetic osteolysis. Fibroblasts in the interface membrane express receptor activator of nuclear factor kappa B ligand (RANKL) and stimulate osteoclast formation. Studies demonstrate that through the control of osteoclastic bone loss bisphosphonates inhibit wear particle-induced bone resorption around total hip arthroplasty. The majority of bisphosphonates studies have focused on their effects on osteoblasts and osteoclasts. Little attention has been paid to their action on fibroblasts. Methods We isolated fibroblasts from the interface membrane that was obtained when revision hip arthroplasty was performed because of aseptic loosening. Fibroblasts were stimulated with alendronate. RANKL and osteoprotegerin (OPG) assays were performed using enzyme-linked immunosorbent assay kit and real time Reverse Transcription- Polymerase Chain Reaction (RT-PCR). Results We found that alendronate stimulated OPG mRNA and protein expression in a time and dose dependent manner. By contrast, alendronate did not affect RANKL expression. Conclusions The results indicate that alendronate modulated OPG production by fibroblasts from periprosthetic membrane, which may prove helpful for the inhibition of bone loss during aseptic loosening following total joint arthroplasty.

[1]  Xianlong Zhang,et al.  Substance P enhanced titanium particles-induced RANKL expression in fibroblasts from periprosthetic membrane , 2013, Connective tissue research.

[2]  D. Tipton,et al.  Effect of bisphosphonates on human gingival fibroblast production of mediators of osteoclastogenesis: RANKL, osteoprotegerin and interleukin-6. , 2011, Journal of periodontal research.

[3]  E. Schwarz,et al.  Differential effects of biologic versus bisphosphonate inhibition of wear debris‐induced osteolysis assessed by longitudinal micro‐CT , 2008, Journal of orthopaedic research : official publication of the Orthopaedic Research Society.

[4]  Xianlong Zhang,et al.  Substance P stimulates production of interleukin 1beta and tumor necrosis factor alpha in fibroblasts from hip periprosthetic membrane. , 2008, The Journal of arthroplasty.

[5]  Xianlong Zhang,et al.  Substance P augments PGE2 and IL-6 production in titanium particles-stimulated fibroblasts from hip periprosthetic membrane. , 2007, Journal of biomedical materials research. Part A.

[6]  T. Glant,et al.  The role of fibroblasts and fibroblast-derived factors in periprosthetic osteolysis. , 2006, Arthritis and rheumatism.

[7]  Yong Zhou,et al.  Effects of bone cement particles on the function of pseudocapsule-derived fibroblasts , 2006, Acta orthopaedica.

[8]  I. Martin,et al.  Effects of bisphosphonates on proliferation and osteoblast differentiation of human bone marrow stromal cells. , 2005, Biomaterials.

[9]  S. Santavirta,et al.  Pseudosynovial fluid from loosened total hip prosthesis induces osteoclast formation. , 2005, Journal of biomedical materials research. Part B, Applied biomaterials.

[10]  E. Schwarz,et al.  Fibroblasts Express RANKL and Support Osteoclastogenesis in a COX‐2‐Dependent Manner After Stimulation With Titanium Particles , 2005, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[11]  S. Santavirta,et al.  Interface tissue fibroblasts from loose total hip replacement prosthesis produce receptor activator of nuclear factor-kappaB ligand, osteoprotegerin, and cathepsin K. , 2005, The Journal of rheumatology.

[12]  P. J. Drury,et al.  A randomized clinical trial comparing oral alendronate and intravenous pamidronate for the treatment of Paget's disease of bone. , 2004, Bone.

[13]  J. Rodriguez-Portales,et al.  Ten years' experience with alendronate for osteoporosis in postmenopausal women. , 2004, The New England journal of medicine.

[14]  H. Zreiqat,et al.  Factors regulating osteoclast formation in human tissues adjacent to peri-implant bone loss: expression of receptor activator NFkappaB, RANK ligand and osteoprotegerin. , 2004, Biomaterials.

[15]  Chia-Chen Hsu,et al.  The effect of alendronate on bone mineral density in the distal part of the femur and proximal part of the tibia after total knee arthroplasty. , 2003, The Journal of bone and joint surgery. American volume.

[16]  S. Santavirta,et al.  Imbalance of RANKL/RANK/OPG system in interface tissue in loosening of total hip replacement. , 2003, The Journal of bone and joint surgery. British volume.

[17]  W. Maksymowych Bisphosphonates for arthritis--a confusing rationale. , 2003, The Journal of rheumatology.

[18]  J. Devogelaer New uses of bisphosphonates: osteogenesis imperfecta. , 2002, Current opinion in pharmacology.

[19]  J. Jurvelin,et al.  Effect of Alendronate on Periprosthetic Bone Loss After Total Knee Arthroplasty: A One-Year, Randomized, Controlled Trial of 19 Patients , 2002, Calcified Tissue International.

[20]  Kirk E. Smith,et al.  Recombinant Adeno-Associated Virus-Mediated Osteoprotegerin Gene Therapy Inhibits Wear Debris-Induced Osteolysis , 2002, The Journal of bone and joint surgery. American volume.

[21]  C. Christiansen,et al.  Effect of bisphosphonates on cartilage turnover assessed with a newly developed assay for collagen type II degradation products , 2002, Annals of the rheumatic diseases.

[22]  E. Schwarz,et al.  Efficacy of ex vivo OPG gene therapy in preventing wear debris induced osteolysis , 2002, Journal of orthopaedic research : official publication of the Orthopaedic Research Society.

[23]  A. Boskey,et al.  In Vivo RANK Signaling Blockade Using the Receptor Activator of NF‐κB:Fc Effectively Prevents and Ameliorates Wear Debris‐Induced Osteolysis via Osteoclast Depletion Without Inhibiting Osteogenesis , 2002, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[24]  Y. Iwamoto,et al.  Fibroblasts from the inner granulation tissue of the pseudocapsule in hips at revision arthroplasty induce osteoclast differentiation, as do stromal cells , 2002, Annals of the rheumatic diseases.

[25]  P. Aspenberg,et al.  Reduction of instability-induced bone resorption using bisphosphonates: High doses are needed in rats , 2002, Acta orthopaedica Scandinavica.

[26]  J. Jurvelin,et al.  Alendronate Reduces Periprosthetic Bone Loss After Uncemented Primary Total Hip Arthroplasty: A Prospective Randomized Study , 2001, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[27]  Safdar N. Khan,et al.  Bisphosphonate Therapy in Fibrous Dysplasia , 2001, Clinical orthopaedics and related research.

[28]  J. Ingle,et al.  Bisphosphonates directly regulate cell proliferation, differentiation, and gene expression in human osteoblasts. , 2000, Cancer research.

[29]  T. Martin,et al.  Therapeutic approaches to bone diseases. , 2000, Science.

[30]  D. Murray,et al.  Effect of osteoprotegerin and osteoprotegerin ligand on osteoclast formation by arthroplasty membrane derived macrophages , 2000, Annals of the rheumatic diseases.

[31]  G. Passeri,et al.  Bisphosphonates stimulate formation of osteoblast precursors and mineralized nodules in murine and human bone marrow cultures in vitro and promote early osteoblastogenesis in young and aged mice in vivo. , 1998, Bone.

[32]  G. Golomb,et al.  Structurally different bisphosphonates exert opposing effects on alkaline phosphatase and mineralization in marrow osteoprogenitors , 1998, Journal of cellular biochemistry.

[33]  H. Rubash,et al.  The John Charnley Award. Inhibition of wear debris mediated osteolysis in a canine total hip arthroplasty model. , 1997, Clinical orthopaedics and related research.

[34]  C. Trevisan,et al.  Bisphosphonate treatment for osteolysis in total hip arthroplasty. A report of four cases. , 2013, Clinical cases in mineral and bone metabolism : the official journal of the Italian Society of Osteoporosis, Mineral Metabolism, and Skeletal Diseases.

[35]  Francesca Gimigliano,et al.  Periprosthetic bone density as outcome of therapeutic response. , 2010, Clinical cases in mineral and bone metabolism : the official journal of the Italian Society of Osteoporosis, Mineral Metabolism, and Skeletal Diseases.

[36]  三谷 誠 Estrogen specifically stimulates expression and production of osteoprotegerin from rheumatoid synovial fibroblasts , 2005 .

[37]  K. Goa,et al.  Zoledronic acid: a review of its use in the management of bone metastases and hypercalcaemia of malignancy. , 2003, Drugs.